Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Impact of SARS-CoV-2 B.1.1.7 Spike variant on neutralisation potency of sera from individuals vaccinated with Pfizer vaccine BNT162b2

DA Collier, B Meng, IATM Ferreira, R Datir, The CITIID-NIHR BioResource COVID-19 Collaboration, N Temperton, A Elmer, N Kingston, B Graves, LE McCoy, KGC Smith, Bradley JR, J Thaventhiram, L Ceron-Gutierrez, G Barcenas-Morales, M Wills, R Doffinger, View ORCID ProfileRK Gupta
doi: https://doi.org/10.1101/2021.01.19.21249840
DA Collier
1Cambridge Institute of Therapeutic Immunology & Infectious Disease (CITIID), Cambridge, UK
2Department of Medicine, University of Cambridge, Cambridge, UK
3Division of Infection and Immunity, University College London, London, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
B Meng
1Cambridge Institute of Therapeutic Immunology & Infectious Disease (CITIID), Cambridge, UK
2Department of Medicine, University of Cambridge, Cambridge, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
IATM Ferreira
1Cambridge Institute of Therapeutic Immunology & Infectious Disease (CITIID), Cambridge, UK
2Department of Medicine, University of Cambridge, Cambridge, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
R Datir
1Cambridge Institute of Therapeutic Immunology & Infectious Disease (CITIID), Cambridge, UK
2Department of Medicine, University of Cambridge, Cambridge, UK
3Division of Infection and Immunity, University College London, London, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
4The CITIID-NIHR BioResource COVID-19 Collaboration, see appendix for author list
N Temperton
5Viral Pseudotype Unit, Medway School of Pharmacy, University of Kent, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
A Elmer
6NIHR Cambridge Clinical Research Facility, Cambridge, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
N Kingston
6NIHR Cambridge Clinical Research Facility, Cambridge, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
B Graves
6NIHR Cambridge Clinical Research Facility, Cambridge, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
LE McCoy
3Division of Infection and Immunity, University College London, London, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
KGC Smith
1Cambridge Institute of Therapeutic Immunology & Infectious Disease (CITIID), Cambridge, UK
2Department of Medicine, University of Cambridge, Cambridge, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Bradley JR
2Department of Medicine, University of Cambridge, Cambridge, UK
6NIHR Cambridge Clinical Research Facility, Cambridge, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
J Thaventhiram
2Department of Medicine, University of Cambridge, Cambridge, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
L Ceron-Gutierrez
7Department of Clinical Biochemistry and Immunology, Addenbrookes Hospital, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
G Barcenas-Morales
7Department of Clinical Biochemistry and Immunology, Addenbrookes Hospital, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
M Wills
2Department of Medicine, University of Cambridge, Cambridge, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
R Doffinger
7Department of Clinical Biochemistry and Immunology, Addenbrookes Hospital, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
RK Gupta
1Cambridge Institute of Therapeutic Immunology & Infectious Disease (CITIID), Cambridge, UK
2Department of Medicine, University of Cambridge, Cambridge, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for RK Gupta
  • For correspondence: rkg20@cam.ac.uk
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

Abstract

SARS-CoV-2 transmission is uncontrolled in many parts of the world, compounded in some areas by higher transmission potential of the B1.1.7 variant now seen in 50 countries. In addition, many countries are extending the interval between doses of vaccine is being extended in order to expand vaccine coverage. It is unclear whether real world neutralising antibody titres will follow those in clinical trials, particularly in elderly persons, and how this will be impacted by mutations in strains such as B1.1.7. Here we tested immune responses in patients 3 weeks following the first dose of the Pfizer BioNTech vaccine BNT162b2. We also tested neutralising antibody responses against pseudoviruses expressing wild type Spike proteins or expressing 3 key mutations present in B.1.1.7 (deletion 69/70, N501Y, A570D). IgG Spike antibody titres correlated well with neutralisation. We observed a range of neutralisation titres against wild type, with geometric mean titre (GMT) of 24. The vaccine sera exhibited a range of inhibitory dilutions giving 50% neutralisation (ID50) from <1:4 to 3449. However a lower proportion of participants over 80 years old achieved threshold neutralisation titre of >1:4 for 50% neutralisation as compared to those under 80 years old (8/15 versus 8/8 P=0.052) after the first dose. Neutralisation titres were not significantly impacted by the combination of three Spike mutations tested, but were reduced against the full set of Spike mutations present in the B.1.1.7 variant. The highest fold change was approxiamately 6 and the median fold change for the B.1.1.7 variant versus wild type was 3.85 (IQR 2.68-5.28). Further work is needed to establish the impact of these observations on real life vaccine efficacy.

Competing Interest Statement

RKG has received consulting fees from UMOVIS Lab

Funding Statement

This research was supported by the National Institute for Health Research Cambridge Biomedical Research Centre. RKG is supported by a Wellcome Trust Senior Fellowship in Clinical Science

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The study was approved by the East of England Cambridge Central Research Ethics Committee 17 EE 0025.

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

Data are available from the corresponding author on request

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Back to top
PreviousNext
Posted January 20, 2021.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Impact of SARS-CoV-2 B.1.1.7 Spike variant on neutralisation potency of sera from individuals vaccinated with Pfizer vaccine BNT162b2
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Impact of SARS-CoV-2 B.1.1.7 Spike variant on neutralisation potency of sera from individuals vaccinated with Pfizer vaccine BNT162b2
DA Collier, B Meng, IATM Ferreira, R Datir, The CITIID-NIHR BioResource COVID-19 Collaboration, N Temperton, A Elmer, N Kingston, B Graves, LE McCoy, KGC Smith, Bradley JR, J Thaventhiram, L Ceron-Gutierrez, G Barcenas-Morales, M Wills, R Doffinger, RK Gupta
medRxiv 2021.01.19.21249840; doi: https://doi.org/10.1101/2021.01.19.21249840
Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
Citation Tools
Impact of SARS-CoV-2 B.1.1.7 Spike variant on neutralisation potency of sera from individuals vaccinated with Pfizer vaccine BNT162b2
DA Collier, B Meng, IATM Ferreira, R Datir, The CITIID-NIHR BioResource COVID-19 Collaboration, N Temperton, A Elmer, N Kingston, B Graves, LE McCoy, KGC Smith, Bradley JR, J Thaventhiram, L Ceron-Gutierrez, G Barcenas-Morales, M Wills, R Doffinger, RK Gupta
medRxiv 2021.01.19.21249840; doi: https://doi.org/10.1101/2021.01.19.21249840

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (76)
  • Allergy and Immunology (196)
  • Anesthesia (54)
  • Cardiovascular Medicine (489)
  • Dentistry and Oral Medicine (89)
  • Dermatology (56)
  • Emergency Medicine (168)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (211)
  • Epidemiology (5677)
  • Forensic Medicine (3)
  • Gastroenterology (215)
  • Genetic and Genomic Medicine (863)
  • Geriatric Medicine (88)
  • Health Economics (230)
  • Health Informatics (761)
  • Health Policy (390)
  • Health Systems and Quality Improvement (251)
  • Hematology (105)
  • HIV/AIDS (182)
  • Infectious Diseases (except HIV/AIDS) (6471)
  • Intensive Care and Critical Care Medicine (390)
  • Medical Education (117)
  • Medical Ethics (28)
  • Nephrology (91)
  • Neurology (847)
  • Nursing (44)
  • Nutrition (141)
  • Obstetrics and Gynecology (162)
  • Occupational and Environmental Health (258)
  • Oncology (514)
  • Ophthalmology (163)
  • Orthopedics (44)
  • Otolaryngology (105)
  • Pain Medicine (48)
  • Palliative Medicine (21)
  • Pathology (149)
  • Pediatrics (250)
  • Pharmacology and Therapeutics (146)
  • Primary Care Research (114)
  • Psychiatry and Clinical Psychology (965)
  • Public and Global Health (2226)
  • Radiology and Imaging (377)
  • Rehabilitation Medicine and Physical Therapy (174)
  • Respiratory Medicine (312)
  • Rheumatology (109)
  • Sexual and Reproductive Health (80)
  • Sports Medicine (82)
  • Surgery (118)
  • Toxicology (25)
  • Transplantation (34)
  • Urology (42)